Overview
At GenVita, we are on a mission to transform the treatment landscape for rare genetic disorders through innovative gene therapy solutions. Our proprietary technology utilizes a unique delivery system that enhances the efficiency and precision of gene therapy, offering hope to patients who currently have limited treatment options. We have successfully completed the initial stages of our preclinical trials, demonstrating the efficacy and safety of our treatment modality. However, to progress to the next phase of clinical trials and scale our production capabilities, we are seeking an investment of $1,500,000. Our team consists of experienced professionals from the biotech and pharmaceutical industries, ensuring a solid foundation in both the science and commercialization of our technology. Over the past year, we have established key partnerships with top research institutions and have begun discussions with potential pharmaceutical collaborators for future commercialization. This funding will be crucial in enabling us to expand our clinical trial activities and optimize our manufacturing processes. Furthermore, it will assist in growing our skilled team to accelerate development time…
Use of funds
The $1,500,000 will be allocated as follows:
- Clinical Trials: $750,000 for patient recruitment, trial management, and regulatory compliance.
- Manufacturing Scale-Up: $500,000 for enhancing our production process and capacity.
- Team Expansion: $200,000 to hire additional scientists and operational staff.
- Marketing and Collaboration: $50,000 for branding and initiating partnerships with pharmaceutical companies.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.